Biotech Industry, Biotech News, Biotechnology Articles, top pharma companies 2013.#Top #pharma #companies #2013

Posted On Jan 22 2018 by

top pharma companies 2013 Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms. Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing. Cytokinetics cans lead drug after phase 3 ALS wipeout Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial. Step Pharma bags cash for CTPS1 autoimmune R …


Market Access, Pricing, Value and Evidence, Pharma Pricing 2018, 20 – 21 March 2018, pharma conference 2013.#Pharma #conference #2013

Posted On Jan 18 2018 by

Market Access, Pricing, Value and Evidence Carla Deakin, Associate Director, Office for Market Access, NICE Carla DeakinAssociate Director, Office for Market Access (OMA), National Institute for Health and Care Excellence.В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В В Originally a biomedical scientist in the NHS, Carla spent 25 years in the UK Diagnostics industry, gaining both commercial and healthcare. Sebastien Le Roux, VP, Global Market …


2013 so far: the pharmaceutical products making headway in the UK #business #development #pharma

Posted On Dec 28 2017 by

#pharmaceutical products # The pharmaceutical products set to make headway in the UK market, 2013 In the last few decades it s been widely reported that the UK s contribution to new pharmaceutical products has steadily declined overall, but last year broke the trend with a record-breaking 39 projects approved. The biggest slump in relatively recent times was in 1985 when only 11 new products went to market, and activity peaked in 1997 and again in 2010 with 34 product launches respectively. A detailed description of activity can be found here. This year, a new wave of medicines to treat …


Pharmaceutical Industry Outlook 2013, Life Sciences Industry Outlook 2013 #amag #pharma

Posted On Dec 27 2017 by

#pharmaceutical industry overview 2013 # Biopharma Life Sciences Outlook 2013 What are the Biggest Challenges and Opportunities Facing the Biopharma Life Sciences Industry During the Next Year? Pharma executives need to carefully consider their approach as they work to improve health economics and patient outcomes. To address unyielding pricing pressures and the enhanced requirement for clinical innovation, pharma companies should calibrate their drug development life cycle to select drug candidates early in the life cycle based on efficacy and economics, provide the evidence for approval and favorable reimbursements, and maintain a strong market position through post-launch evidence. This is especially …


The top 10 pharma companies by 2013 revenue #usv #pharma

Posted On Dec 27 2017 by

#top pharma companies 2013 # The top 10 pharma companies by 2013 revenue The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises. Pfizer ($PFE) and Merck Co. ($MRK), with ongoing patent issues and reorganizations, saw their positions fall a couple of notches, and AbbVie ($ABBV), having been spun off from Abbott Laboratories ($ABT) at the beginning of the year, didn’t quite make the top 10. Its disappearance allowed Eli Lilly Co. ($LLY) …


Drug Channels: 2013 Pharmacy Market Share for Specialty Drugs – and the Biggest Players #pharmaceuticals #industry

Posted On Nov 26 2017 by

#pharmaceutical companies market share # Our research shows a booming market: In 2013, retail, mail, and specialty pharmacies dispensed about $63 billion in specialty pharmaceuticals. Specialty drugs accounted for 22% of total pharmacy industry revenues. Three companies Express Scripts, CVS Caremark, and Walgreens accounted for 63% of revenues from pharmacy-dispensed specialty drugs. The next three largest players had a combined share of about 5%. Read on for our market share estimates for the top players, observations on the market’s structure, and details of my panel discussion with specialty pharmacy leaders at next week s sPCMA Business Forum . THE NOMINEES …


The top 10 most expensive drugs of 2013 #alnylam #pharma

Posted On Nov 26 2017 by

#pharmaceutical companies news # The top 10 most expensive drugs of 2013 The price of Gilead Sciences’ breakthrough drug Sovaldi has drawn all of the attention this year. By pricing it at $85,000 for a 12-week course, Gilead Sciences ($GILD) has been pilloried by politicians, payers and providers. But as EvaluatePharma points out, at that price Sovaldi barely makes it into the top 20 most expensive drugs. number 19 to be exact, just above Novartis’ ($NVS) Gleevec and just below GlaxoSmithKline’s ($GSK) Mekinist. Sovaldi is pricey, but if you want to talk about really pricey, then look at the 10 …


Top 10 animal health companies of 2013 #pharma #job #search

Posted On Nov 10 2017 by

#leading pharmaceutical companies 2013 # Top 10 animal health companies of 2013 It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound annual rate, faster than the market for human medicines. Zoetis ($ZTS) was spun off from Pfizer ($PFE) as the largest independent animal health company. M A action in recent months is remixing the players once again. Next year, Novartis ($NVS) will be off of this list, and based on current revenues, …


Drug Channels: 2013 Pharmacy Market Share for Specialty Drugs – and the Biggest Players #real #pharma

Posted On Nov 9 2017 by

#pharmaceutical companies market share # Our research shows a booming market: In 2013, retail, mail, and specialty pharmacies dispensed about $63 billion in specialty pharmaceuticals. Specialty drugs accounted for 22% of total pharmacy industry revenues. Three companies Express Scripts, CVS Caremark, and Walgreens accounted for 63% of revenues from pharmacy-dispensed specialty drugs. The next three largest players had a combined share of about 5%. Read on for our market share estimates for the top players, observations on the market’s structure, and details of my panel discussion with specialty pharmacy leaders at next week s sPCMA Business Forum . THE NOMINEES …


The top 10 most expensive drugs of 2013 #natco #pharma

Posted On Nov 8 2017 by

#pharmaceutical companies news # The top 10 most expensive drugs of 2013 The price of Gilead Sciences’ breakthrough drug Sovaldi has drawn all of the attention this year. By pricing it at $85,000 for a 12-week course, Gilead Sciences ($GILD) has been pilloried by politicians, payers and providers. But as EvaluatePharma points out, at that price Sovaldi barely makes it into the top 20 most expensive drugs. number 19 to be exact, just above Novartis’ ($NVS) Gleevec and just below GlaxoSmithKline’s ($GSK) Mekinist. Sovaldi is pricey, but if you want to talk about really pricey, then look at the 10 …